Broker recommendations for GlaxoSmithKline Plc
The GlaxoSmithKline Plc stock is rated at 1.630435 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Wednesday 14 October, 2020 by a total of 23 brokers. This means that the consensus of the 23 different brokers is leaning toward to moderate buy/hold.
Sell
3 (13.04%) Underweight
0 (0%) Hold
8 (34.78%) Overweight
1 (4.35%) Buy
11 (47.83%)
Price target by analysts
The 18 latest analyst estimates, per Thursday 22 October, 2020, show the following high, low and average price targets.
Target Average: 47.94 USD
Target High: 60.41 USD
Target Low: 40.17 USD
GlaxoSmithKline (GSK) to Release Earnings on Wednesday
Saturday, 24 October 2020, 09:50:49
GlaxoSmithKline (NYSE:GSK) will be posting its quarterly earnings results before the market opens on Wednesday, October 28th. Analysts expect GlaxoSmithKline to post earnings of $0.78 per share for the quarter. GlaxoSmithKline has set its FY 2020 Pre-Market guidance at 1.56-1.60 EPS. GlaxoSmithKline (NYSE:GSK) last announced its earnings results on Wednesday, July 29th. The pharmaceutical company […]
— US Banking News
To Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Competitors
Saturday, 24 October 2020, 06:00:00
The hunt for a solution to Covid-19 is producing an unlikely team of rivals in the cutthroat world of pharmaceuticals
— The Wall Street Journal
GlaxoSmithKline (NYSE:GSK) Stock Rating Reaffirmed by JPMorgan Chase & Co.
Friday, 23 October 2020, 03:32:41
GlaxoSmithKline (NYSE:GSK)‘s stock had its “neutral” rating restated by stock analysts at JPMorgan Chase & Co. in a note issued to investors on Wednesday, Borsen Zeitung reports. A number of other brokerages have also recently commented on GSK. UBS Group reissued a “buy” rating on shares of GlaxoSmithKline in a research note on Monday, October […]
— The Lincolnian
GlaxoSmithKline PLC Holding(s) in Company
Thursday, 22 October 2020, 13:34:00
GlaxoSmithKline PLC 22 October 2020 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent…
— ADVFN UK
Drug Repurposing Market Expected to Deliver Dynamic Progression until 2026 | Major Players GlaxoSmithKline, Atomwise, Biovista, Inc., Centene Corporation, NuMedii
Thursday, 22 October 2020, 12:27:03
The global drug repurposing market experiences growth due to shorter drug development time for repurposed drugs compared to new chemical entities. In addition, advances in the computational power to process large databases has allowed cost-effective solutions to approach drug development.
— OpenPR
We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.
